LEXINGTON, Mass., Oct. 9, 2015 /PRNewswire/ -- Pulmatrix, Inc., (NASDAQ: PULM) will be webcasting the Company's investor presentation at two upcoming investor conferences.
Pulmatrix will be presenting at the Dawson James 2015 Small Cap Growth Stock Conference on Thursday, October 15, 2015 at 8:30 am EDT. Additionally, the Company will be presenting at the 14th Annual BIO Investor Forum on Tuesday, October 20, 2015 at 11:00 am PDT (2:00 pm EDT).
A live webcast of the presentations may be accessed in the investors section of the Company's website at www.pulmatrix.com. A replay of the presentations will be available on the Company's website for 90 days following the presentation.
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis (CF), as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis. In addition, Pulmatrix is pursuing opportunities in major pulmonary diseases through collaborations, including PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD). Pulmatrix's product candidates are based on iSPERSE™, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
SOURCE Pulmatrix, Inc.